Our study demonstrated that PP2A inhibitors can increase the expression of B7-H3 in malignant meningiomas; therefore, the combination of LB-100 and B7-H3 inhibitors may become a new and effective treatment method for malignant meningiomas. The gene discussed is CD276; the disease is Anaplastic (Malignant) Meningioma.